Trials / Completed
CompletedNCT00635414
Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously
An Open, Randomized, Two-way Crossover Study Comparing the Effect of 40mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD).
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study looks at the effect on basal and pentagastrin-stimulated acid output of 40 mg Esomeprazole (Nexium) administered orally and intravenously as a 15-minute infusion to people with symptoms of Gastroesophageal Reflux Disease (GERD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Esomeprazole | 40mg oral |
| DRUG | Esomeprazole | 15 minute intravenous infusion |
Timeline
- Start date
- 2002-08-01
- Primary completion
- 2002-10-01
- Completion
- 2002-10-01
- First posted
- 2008-03-13
- Last updated
- 2011-01-25
Source: ClinicalTrials.gov record NCT00635414. Inclusion in this directory is not an endorsement.